Oppenheimer Asset Management Inc. Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Oppenheimer Asset Management Inc. grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 17.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,360 shares of the medical research company’s stock after purchasing an additional 1,974 shares during the period. Oppenheimer Asset Management Inc.’s holdings in IQVIA were worth $3,166,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of IQV. 1832 Asset Management L.P. raised its stake in shares of IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares during the period. Renaissance Technologies LLC acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $70,610,000. Impax Asset Management Group plc raised its stake in shares of IQVIA by 19.3% during the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after buying an additional 264,555 shares during the period. Canada Pension Plan Investment Board raised its stake in shares of IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after buying an additional 211,653 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its stake in shares of IQVIA by 285.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after buying an additional 198,808 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on IQV. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research note on Friday, November 1st. TD Cowen reduced their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Robert W. Baird reduced their price objective on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. reduced their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Finally, UBS Group increased their price objective on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $259.13.

IQVIA Stock Down 5.1 %

Shares of IQV opened at $192.63 on Friday. IQVIA Holdings Inc. has a 52-week low of $189.63 and a 52-week high of $261.73. The company has a market capitalization of $34.96 billion, a PE ratio of 25.28, a price-to-earnings-growth ratio of 2.17 and a beta of 1.51. The stock has a fifty day simple moving average of $227.96 and a two-hundred day simple moving average of $228.59. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.